AC
EPIX

Aldebaran Capital’s ESSA Pharma EPIX Stock Holding History

Aldebaran Capital’s Portfolio EPIX Stock Details EPIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-578,939
Closed -$984K – 34
2025
Q2 		$984K Buy
578,939
+9,645
+2% +$16.3K 0.97% 23
2025
Q1 		$899K Buy
569,294
+171,771
+43% +$291K 0.85% 24
2024
Q4 		$712K Buy
+397,523
New +$1.27M 0.68% 27

Other funds holding EPIX

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
LP
LMR Partners London, United Kingdom $26.8B AUM 68.38% 1-Year Est. Return
SC
Shay Capital New York $1.56B AUM 46.17% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Aldebaran Capital's EPIX Position: Q3 2025 in Review

Aldebaran Capital sold out of ESSA Pharma (EPIX) in Q3 2025, closing a stake of 578,939 shares — an estimated $984K sold.

Aldebaran Capital first reported a position in EPIX in Q4 2024 and held it in 3 quarters. The position peaked at $984K in Q2 2025. 32 funds tracked by Wall St. Rank hold EPIX as of Q3 2025.

  • Aldebaran Capital reported no remaining ESSA Pharma position as of Q3 2025 after selling out during the quarter.
  • Aldebaran Capital sold 578,939 ESSA Pharma shares in Q3 2025, an estimated $984K.
  • Aldebaran Capital first reported a position in ESSA Pharma in Q4 2024 and held it in 3 quarters.
  • Aldebaran Capital's ESSA Pharma position peaked at $984K in Q2 2025.
  • 32 funds tracked by Wall St. Rank held ESSA Pharma as of Q3 2025.

Based on Aldebaran Capital's 13F filing for Q3 2025, filed 10 Nov 2025.